A Prospective Double-Blind Study of Retrovir in Early HIV Infection

Completed · Not applicable

Conditions studied: HIV Infections

In brief

To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients. (12/01/89) Information supplied by drug company update. Study discontinued due to positive data from ACTG 016.

Key facts

Study ID

NCT00002045

Run by

Glaxo Wellcome

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Treatment:
• Allowed:
• Electron beam therapy to an area of less than 100 cm2.
• Patient must have signs and symptoms of HIV infection confined to those of stages WRII-V or CDC groups III IV-A, IV-C-2 (except recurrent Salmonella bacteremia, nocardiosis, or disseminated/extrapulmonary Mycobacterium tuberculosis), and IV-E (except diffuse interstitial lymphoid pneumonitis).
• Patient must be able to give informed consent.

You may not qualify if…

• Co-existing Condition:
• Patients with the following are excluded:
• Evidence of nervous system dysfunction caused by factors other than HIV infection, including chronic alcohol or drug abuse.
• Present or prior known AIDS-defining opportunistic infections, lymphomas, or malignancies based on CDC criteria.
• Present or prior known systemic opportunistic diseases most recently included in the expanded CDC definition of AIDS:
• extrapulmonary or disseminated Mycobacterium tuberculosis infections, recurrent nontyphoidal Salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid pneumonitis.
• Evidence of compromised bone marrow function defined by specified lab values.
• Evidence of HIV neurologic disease.
• Evidence of HIV-associated "wasting syndrome".
• Hypersensitivity to zidovudine (AZT).
• Concurrent Medication:
• Excluded:
• Cytotoxic chemotherapeutic agents.
• Steroids.
• Interferon or immunomodulating agents.
• Any antiretroviral drug including, but not limited to zidovudine (AZT), ribavirin, HPA23, AL 721, or phosphonoformate.
• Patients with the following are excluded:
• Evidence of nervous system dysfunction caused by factors other than HIV infection, including chronic alcohol or drug abuse. Present or prior known AIDS-defining opportunistic infections, lymphomas, or malignancies based on CDC criteria. Present or prior known systemic opportunistic diseases most recently included in the expanded CDC definition of AIDS:
• extrapulmonary or disseminated Mycobacterium tuberculosis infections, recurrent nontyphoidal Salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid pneumonitis.
• Evidence of compromised bone marrow function defined by specified lab values. Evidence of HIV neurologic disease.
• Evidence of HIV-associated wasting syndrome.
• Hypersensitivity to retrovir.
• Prior Medication:
• Excluded within 4 weeks of study entry:
• Interferon.

Where it is running

• Glaxo Wellcome Inc — Research Triangle Park, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.